

LITERATURA

1. Trapani G, Altomare C, Sanna E, Biggio G, Liso G. Propofol in anesthesia: mechanism of action, structure-activity relationships, and drug delivery. *Curr Med Chem*. 2000;7(2):249-271. doi: 10.2174/0929867003375335.
2. Sun NCH, Wong AYC, Irwin MG. A comparison of pain on intravenous injection between two preparations of propofol. *Anesth Analg*. 2005;101(3):675-678. doi: 10.1213/01.ANE.0000157564.91910.04.
3. Liljeroth E, Åkeson J. Less local pain on intravenous infusion of a new propofol emulsion. *Acta Anaesthesiol Scand*. 2005;49(2):248-251. doi: 10.1111/j.1399-6576.2004.00573.x.
4. Meidert AS, Rucz P, Angster J, Esser J, Miklós A, Schelling G. Photoacoustic detection of propofol in breath gas for monitoring depth of anaesthesia: from bench to bedside. *Br J Anaesth*. 2025;135(5):1203-1211. doi: 10.1016/j.bja.2025.07.080.
5. Kuck K, Hornuss C. Propofol is in the air: can exhaled gas monitoring illuminate intravenous dosing? *Br J Anaesth*. 2025;135(5):1144-1146. doi: 10.1016/j.bja.2025.08.006.
6. Bleeker C, Vree T, Lagerwerf A, Willems-van Bree E. Recovery and long-term renal excretion of propofol, its glucuronide, and two di-isopropylquinol glucuronides after propofol infusion during surgery. *Br J Anaesth*. 2008;101(2):207-212. doi: 10.1093/bja/aen134.
7. Lasica A, Cortesi C, Milani GP, Bianchetti MG, Schera FM, Camozzi P, et al. Propofol-associated urine discoloration: systematic literature review. *Pharmacology*. 2023;108(5):415-422. doi: 10.1159/000533327.
8. Astapenko D, Černý V. Barva moči z pohledu klinické fyziologie. *Anest intenziv Med*. 2022;33(3-4):177-178. doi: 10.36290/aim.2022.031.
9. Sears S, Hewett SJ. Influence of glutamate and GABA transport on brain excitatory/inhibitory balance. *Exp Biol Med* (Maywood). 2021;246(9):1069-1083. doi: 10.1177/1535370221989263.
10. Jiang J, Jiao Y, Gao PO, Yin W, Zhou W, Zhang Y, et al. Propofol differentially induces unconsciousness and respiratory depression through distinct interactions between GABAA receptor and GABAergic neuron in corresponding nuclei. *Acta Biochim Biophys Sin*. 2021;53(8):1076-1087. doi: 10.1093/abbs/gmab084.
11. Huang Z, Mashour GA, Hudetz AG. Propofol disrupts the functional core-matrix architecture of the thalamus in humans. *figshare* [Internet]. 2024 [cited 2026 May 25]. doi: 10.6084/M9.FIGSHARE.25927939.
12. Malekmohammadi M, Price CM, Hudson AE, DiCesare JAT, Pouratian N. Propofol-induced loss of consciousness is associated with a decrease in thalamocortical connectivity in humans. *Brain*. 2019;142(8):2288-2302. doi: 10.1093/brain/awz169.
13. Song XX, Yu BW. Anesthetic effects of propofol in the healthy human brain: functional imaging evidence. *J Anesth*. 2015;29(2):279-288. doi: 10.1007/s00540-014-1889-4.
14. Gupta A, Stierer T, Zuckerman R, Sakima N, Parker SD, Fleisher LA. Comparison of recovery profile after ambulatory anesthesia with propofol, isoflurane, sevoflurane and desflurane: a systematic review. *Anesth Analg*. 2004;98(3):632-641. doi: 10.1213/01.ANE.0000103187.70627.57.
15. Tramèr M, Moore A, McQuay H. Meta-analytic comparison of prophylactic antiemetic efficacy for postoperative nausea and vomiting: propofol anaesthesia vs omitting nitrous oxide vs total i.v. anaesthesia with propofol. *Br J Anaesth*. 1997;78(3):256-259. doi: 10.1093/bja/78.3.256.
16. Kampo S, Afful AP, Mohammed S, Ntim M, Buunaaim ADB, Anabah TW. Sub-hypnotic dose of propofol as antiemetic prophylaxis attenuates intrathecal morphine-induced postoperative nausea and vomiting, and pruritus in parturient undergoing cesarean section: a randomized control trial. *BMC Anesthesiol*. 2019;19(1):177. doi: 10.1186/s12871-019-0847-y.
17. Krajčová A, Waldauf P, Anděl M, Duška F. Propofol infusion syndrome: a structured review of experimental studies and 153 published case reports. *Crit Care*. 2015;19:398. doi: 10.1186/s13054-015-1112-5.
18. Hemphill S, McMenamin L, Bellamy MC, Hopkins PM. Propofol infusion syndrome: a structured literature review and analysis of published case reports. *Br J Anaesth*. 2019;122(4):448-459. doi: 10.1016/j.bja.2018.12.025.
19. Mirrakhimov AE, Voore P, Halytskyy O, Khan M, Ali AM. Propofol infusion syndrome in adults: a clinical update. *Crit Care Res Pract*. 2015;2015:260385. doi: 10.1155/2015/260385.
20. Stovell M, Smith S, Udberg M, Loh W, Nair P. Pre-PRIS? Prospective monitoring for early markers of propofol infusion syndrome. *Crit Care*. 2013;17(Suppl 2):P391. doi: 10.1186/cc12329.
21. Khodadadi M, Mohsenzadeh M, Eghbalian M, Pouladkhay F. Biochemical and pharmacological characterization of propofol infusion syndrome risk markers following high-dose propofol. *Sci Rep*. 2026;16:2038. doi: 10.1038/s41598-025-31739-y.
22. Djahel C, Marois C, Cosme L, Hayatou Z, Braham Ghedira N, Calonge Q, et al. Propofol-related biological alterations and incidence of propofol infusion syndrome in status epilepticus: a 10-year cohort study. *Front Neurol*. 2026;16:1753979. doi: 10.3389/fneur.2025.1753979.